Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Overview of attention for article published in The Lancet, July 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

news: 10 news outlets
policy: 3 policy sources
twitter: 32 X users
patent: 3 patents

facebook: 3 Facebook pages
f1000: 1 research highlight platform
guideline: 2 clinical guideline sources

Readers on

mendeley: 535 Mendeley

So far, Altmetric has seen 11 news stories from 10 outlets.

PTC Therapeutics: Sarepta Déjà Vu Or A Return To Scientific Standards?

Seeking Alpha, 21 Sep 2017

Summary The fate of PTC Therapeutics's Translarna (ataluren) will be decided September 28 during an advisory committee meeting.

NeuroBreak: FINGER Trial Comes to U.S.; Migraine Drug Moves Along

MedPage Today, 25 Jul 2017

MedpageToday by Kristina Fiore Deputy Managing Editor, MedPage Today July 25, 2017 The Alzheimer's Association will spend $20…

Clinical trial shows some promise for Duchenne muscular dystrophy drug

Today Topics , 20 Jul 2017

The results of an international clinical trial, led in part by a UC Davis School of Medicine expert, have shown that a drug…

Clinical Trial Shows Some Promise for Duchenne Muscular Dystrophy Drug

Seattle Post-Intelligencer, 19 Jul 2017

PRWeb Published 7:20 pm, Tuesday, July 18, 2017 The results of an international clinical trial, led in part by a UC Davis…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 7 additional news stories.